<DOC>
	<DOC>NCT00124436</DOC>
	<brief_summary>Patients who have been treated in study protocol BAP089 may have responded to treatment, and subsequently relapsed to &gt;75% of the baseline disease severity, will be investigated for response to further treatment with alitretinoin. Also, patients who have responded with mild or moderate disease will be investigated for additional treatment effect after prolongated treatment.</brief_summary>
	<brief_title>Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Hand Dermatoses</mesh_term>
	<mesh_term>Alitretinoin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>Previous participation in protocol BAP089 Response of severe, treatment refractory hand dermatitis with mild or moderate, or responding patients who relapsed to 75% of baseline disease Female patients who are pregnant or who want to become pregnant Female patients of child bearing potential who cannot use or who will not commit to using two effective methods of contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Patients who have been enrolled in study protocol BAP089, and whose severe chronic hand dermatitis responded with mild or moderate disease, or who relapsed</keyword>
</DOC>